Koliani-Pace, J. L., Singh, S., Luo, M., Hirten, R., Aniwan, S., Kochhar, G., Chang, S., Lukin, D., Gao, Y., Bohm, M., Swaminath, A., Gupta, N., Shmidt, E., Meserve, J., Winters, A., Chablaney, S., Faleck, D. M., Yang, J., Huang, Z., Boland, B. S., Shashi, P., Weiss, A., Hudesman, D., Varma, S., Fischer, M., Sultan, K., Shen, B., Kane, S., Loftus, E. V., Sands, B. E., Colombel, J., Sandborn, W. J., Lasch, K., Siegel, C. A., & Dulai, P. S. (2019). changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. Inflammatory bowel diseases, 25(11), 1854–1861. http://access.bl.uk/ark:/81055/vdc_100126060133.0x00003e